Skip to main content

Table 2 Background of second-line anti-VEGF drug trials

From: Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer

Trial ML18147 Ref. [11] RAISE Ref. [4] VELOUR Ref. [3]
Number of cases 820 1072 1226
Prior oxaliplatin 41.8% 100% 100%
Prior bevacizumab 100% 100% 30.5%
Backbone chemotherapy Irinotecan (35%) FOLFIRI FOLFIRI
Design Open label Double blind Double blind
Combination With BEV Without BEV With RAM Without RAM With AFL Without AFL
ORR 5% 3% 13.4% 12.5% 19.8% 11.1%
PFS (months) 5.7 4.1 5.7 4.5 6.90 4.67
  HR 0.68 p < .0001 HR0.793 p < .0005 HR0.758 p < .0001
OS (months) 11.2 9.8 13.3 11.7 13.50 12.06
  HR 0.81 p = .0062 HR 0.844 p = .0219 HR 0.817 p = .0032
  1. ORR overall response rate, PFS progression-free survival, OS overall survival, BEV bevacizumab, RAM ramucirumab, AFL aflibercept
\